Testosterone Recovery Linked to Overall Survival in High-Risk Prostate Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 18, 2025 -- Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients with high-risk prostate cancer receiving radiotherapy and long-term androgen deprivation therapy (ADT), according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
Abdenour Nabid, M.D., from Centre Hospitalier Universitaire de Sherbrooke in Quebec, Canada, and colleagues randomly assigned 630 patients with high-risk prostate cancer to pelvic radiotherapy plus 36 versus 18 months of ADT (310 and 320 patients, respectively). Serum T was collected at baseline and regularly thereafter. T recovery was defined as return of T to within the normal range value of each participating institution. T data were available for 515 patients who were retained for the analysis.
Overall, 6,587 T measurements were available during a period of 22 years (median follow-up, 17.4 years). The researchers found that 52.4 percent of patients recovered T to normal levels: 57.0 and 44.3 percent in the 18- and 36-month cohorts, respectively. Patients not recovering T to a normal level were older, had higher clinical stage, and had diabetes. The median time to T recovery was 3.6 years among patients regaining T to a normal level. The 10- and 15-year overall survival rates were 76 and 44 percent, respectively, among those recovering T versus 55 and 30 percent, respectively, for those not recovering T. When considering the global hazard ratio, a significantly lower risk for death favored patients recovering T (hazard ratio, 0.54).
"The increased death rate in patients not recovering T is likely due to causes unrelated to prostate cancer," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Racial Differences Seen in Prostate Cancer Care Quality
WEDNESDAY, July 30, 2025 -- Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared with White men, according to a...
Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer
TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.